ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Launches collaborative centre for translational research in head and neck cancer
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Subscribe To Our Newsletter & Stay Updated
